Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $10.7000 (-4.63%) ($10.7000 - $10.7000) on Wed. Mar. 3, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.07% (three month average) | RSI | 10 | Latest Price | $10.7000(-4.63%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -2% a day on average for past five trading days. | Weekly Trend | FOLD declines -12% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Rotation from growth to value for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(57%) IWO(53%) XBI(51%) IWM(50%) IWC(48%) | Factors Impacting FOLD price | FOLD will decline at least -2.535% in a week (0% probabilities). VIXM(-30%) VXX(-14%) UUP(-12%) UNG(-6%) IGOV(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.535% (StdDev 5.07%) | Hourly BBV | -1.8 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-33.22(-410.47%) | Resistance Level | $14.4 | 5 Day Moving Average | $11.59(-7.68%) | 10 Day Moving Average | $11.76(-9.01%) | 20 Day Moving Average | $14.4(-25.69%) | To recent high | -57% | To recent low | 0% | Market Cap | $2.763b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |